Arrivent Biopharma, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
ArriVent BioPharma is registering an additional 1,597,223 shares of common stock following its initial public offering.
NASDAQ
ArriVent BioPharma is moving forward with its IPO, offering 8,333,333 shares of common stock with an estimated price range of $17.00 to $19.00 per share.
NASDAQ
ArriVent BioPharma amends its S-1 filing for an initial public offering of 8.3 million shares, aiming to fund furmonertinib development and pipeline expansion.